SCHEMBL3011283

SCHEMBL3011283

CCOc1ccc(Cc2csc(N3CCN(S(=O)(=O)c4c(F)cccc4F)CC3)n2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 5/20 0.43
PKLR P30613 4/20 0.43
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
MAPT P10636 5/20 0.41
USP2 O75604 2/20 0.41
RECQL P46063 1/20 0.41
HSD17B10 Q99714 1/20 0.41
MAPK1 P28482 3/20 0.40
LMNA P02545 3/20 0.40
AR P10275 1/20 0.39
TSHR P16473 2/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
GBA1 P04062 1/20 0.39
SMN1; SMN2 Q16637 4/20 0.38
ALDH1A1 P00352 2/20 0.38
TDP1 Q9NUW8 1/20 0.38
TP53 P04637 1/20 0.38
THRB P10828 1/20 0.38
KDM4E B2RXH2 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3018873 0.91 MEN1 (0.41) PKMMEN1KMT2AMAPTUSP2
SCHEMBL3011121 0.91 PKM (0.55) PKMPKLRKMT2AMAPTUSP2
SCHEMBL3018745 0.89 PKM (0.47) PKMPKLRMEN1KMT2AMAPT
SCHEMBL3015536 0.88 PKM (0.45) PKMPKLRMEN1KMT2AMAPT
SCHEMBL3011037 0.88 PKM (0.47) PKMPKLRMEN1KMT2AMAPT
SCHEMBL3007892 0.86 MAPT (0.47) MEN1KMT2AMAPTUSP2RECQL
SCHEMBL3015815 0.86 PKM (0.50) PKMPKLRMEN1KMT2AMAPT
SCHEMBL3019523 0.86 ALDH1A1 (0.55) PKMMEN1KMT2AMAPTUSP2
SCHEMBL3011177 0.85 PKM (0.47) PKMPKLRMEN1KMT2AMAPT
SCHEMBL3013107 0.85 AR (0.38) PKMPKLRMEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA PKM 1047/4885PKLR 2799/4885MEN1 454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.